<DOC>
	<DOCNO>NCT00165867</DOCNO>
	<brief_summary>The overall purpose study determine efficacy , safety tolerability indisulam combination irinotecan treatment patient metastatic colorectalcancer previously treat 5-fluorouracil/leucovorin oxaliplatin ( FOLFOX ) .</brief_summary>
	<brief_title>An Open Label Phase II Study Indisulam Combination With Irinotecan Patients With Metastatic Colorectal Cancer Who Have Been Previously Treated With 5-Fluorouracil/Leucovorin Oxaliplatin</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Inclusion criterion : Ambulant male female patient metastatic colorectal cancer previously treat 5fluorouracil/leucovorin oxaliplatin . Patients must fulfill follow criterion include study : At least 4 dos previous treatment oxaliplatin All previous treatment ( include surgery radiotherapy ) must complete least four week prior study entry acute toxicity must resolve At least one unidimensionally measurable lesion accord RECIST criterion ( follow qualify measurable lesion : bone , leptomeningeal disease , ascites , pleural/pericardial effusion , lymphangitis cutis/pulmonis , abdominal mass confirm followed imaging technique , cystic lesion ) Aged great equal 18 year Histologically cytologically confirm colorectal cancer Karnofsky performance status great equal 70 % Written inform consent participate study Exclusion criterion : Patients follow characteristic include study : More three previous line chemotherapy ( include neoadjuvant adjuvant ) Prior treatment cytotoxics 5 fluorouracil/leucovorin ( capecitabine UFT permit ) oxaliplatin . Prior epidermal growth factor receptor target antiangiogenic therapy permit . Untreated brain metastasis ( patient treat CNS metastasis must asymptomatic radiologically stable 4 week prior entry ) . Patients must clinical symptom brain metastasis must take corticosteroid treatment brain metastasis . Patients must leptomeningeal metastasis Any follow laboratory parameter : 1. hemoglobin &lt; 10 g/dl ; 2. neutrophil &lt; 1.5 x 109/L ; 3. platelet &lt; 100 x 109/L ; 4. serum bilirubin &gt; 25 mmol/l ( 1.5 mg/dl ) ; 5. liver parameter &gt; 2.5 x upper normal limit ( ULN ) ( &gt; 5 x upper normal limit presence hepatic metastasis ) ; 6. serum creatinine &gt; 1.5 x ULN ; 7. serum calcium ( correct albumin ) &gt; =11.5 mg/dl . 5 . History Gilbert â€™ Disease conjugate hyperbilirubinemia 6 . Concurrent previous malignancy different tumor type within five year start study except adequately treat non melanoma skin cancer cervical intraepithelial neoplasia Uncontrolled infection Clinically significant cardiac impairment unstable ischemic heart disease include myocardial infarction within six month study start Chronic inflammatory bowel disease and/or bowel obstruction History hypersensitivity sulfonamides History severe hypersensitivity reaction one excipients irinotecan Treatment within two week start stud following : coumarin anticoagulant , terfenadine , cisapride , cyclosporin , tacrolimus , theophylline , diazepam , sulphonylurea hypoglycaemics , phenytoin , carbamazepine Any treatment investigational drug within 30 day start study Pregnancy lactation ( woman childbearing potential must negative pregnancy test inclusion study ; postmenopausal woman must amenorrheic least 12 month ) . Female patient must use adequate contraceptive protection Fertile male willing use contraception whose female partner use adequate contraceptive protection History alcoholism , drug addiction , psychiatric psychological condition , opinion investigator , would impair study compliance . Legal incapacity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2006</verification_date>
</DOC>